Incidence of invasive pneumococcal disease after introduction of the 13-valent conjugate pneumococcal vaccine in British Columbia: A retrospective cohort study.
Adolescent
Adult
Aged
Aged, 80 and over
British Columbia
/ epidemiology
Child
Child, Preschool
Female
Humans
Incidence
Infant
Infant, Newborn
Male
Middle Aged
Pneumococcal Infections
/ epidemiology
Pneumococcal Vaccines
/ immunology
Retrospective Studies
Serogroup
Streptococcus pneumoniae
/ classification
Survival Rate
Young Adult
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
20
03
2020
accepted:
14
09
2020
entrez:
30
9
2020
pubmed:
1
10
2020
medline:
16
12
2020
Statut:
epublish
Résumé
A significant reduction in invasive pneumococcal disease (IPD) has been reported, across all ages, following the implementation of 7-valent conjugate pneumococcal vaccine (PCV7) globally, as part of infant immunization programs. We explored the additional impact of PCV13 on IPD over a 14-year period. Using provincial laboratory surveillance and hospitalization data (N = 5791), we calculated the annual incidence of IPD following the implementation of PCV13 vaccine. Poisson regression was used to evaluate changes in the overall incidence of IPD, and serotype-specific IPD between PCV7 (2004-10) and PCV13 (2011-2015) eras. Overall, IPD rates have seen a modest decline in the PCV13 compared to the PCV7 era (IRR 0.84; 95% CI: 0.79-0.89); this was seen in children ≤2 years of age, and the majority of the adult cohort. Rates of vaccine-type IPD (PCV7 and PCV13) also decreased in the PCV13 era. In contrast, IPD incidence related to non-PCV13 (IRR: 1.56; 95%CI:1.43-1.72) and non-vaccine serotypes (IRR: 2.12; 95%CI:1.84-2.45) increased in the PCV13 era compared to the PCV7 era. A modest reduction in IPD from the PCV13 vaccine was observed, with gains limited to the immunized cohort and adults. However, a significant increase in non-vaccine serotypes emphasizes the need for continued surveillance.
Sections du résumé
BACKGROUND
A significant reduction in invasive pneumococcal disease (IPD) has been reported, across all ages, following the implementation of 7-valent conjugate pneumococcal vaccine (PCV7) globally, as part of infant immunization programs. We explored the additional impact of PCV13 on IPD over a 14-year period.
METHODS
Using provincial laboratory surveillance and hospitalization data (N = 5791), we calculated the annual incidence of IPD following the implementation of PCV13 vaccine. Poisson regression was used to evaluate changes in the overall incidence of IPD, and serotype-specific IPD between PCV7 (2004-10) and PCV13 (2011-2015) eras.
RESULTS
Overall, IPD rates have seen a modest decline in the PCV13 compared to the PCV7 era (IRR 0.84; 95% CI: 0.79-0.89); this was seen in children ≤2 years of age, and the majority of the adult cohort. Rates of vaccine-type IPD (PCV7 and PCV13) also decreased in the PCV13 era. In contrast, IPD incidence related to non-PCV13 (IRR: 1.56; 95%CI:1.43-1.72) and non-vaccine serotypes (IRR: 2.12; 95%CI:1.84-2.45) increased in the PCV13 era compared to the PCV7 era.
CONCLUSIONS
A modest reduction in IPD from the PCV13 vaccine was observed, with gains limited to the immunized cohort and adults. However, a significant increase in non-vaccine serotypes emphasizes the need for continued surveillance.
Identifiants
pubmed: 32997698
doi: 10.1371/journal.pone.0239848
pii: PONE-D-20-08116
pmc: PMC7526878
doi:
Substances chimiques
13-valent pneumococcal vaccine
0
Pneumococcal Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0239848Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
PLoS One. 2018 May 25;13(5):e0195799
pubmed: 29799839
Lancet. 2006 Oct 28;368(9546):1495-502
pubmed: 17071283
Lancet Infect Dis. 2018 Apr;18(4):441-451
pubmed: 29395999
Eur J Clin Microbiol Infect Dis. 2017 Mar;36(3):575-583
pubmed: 27844262
Can J Microbiol. 2013 Dec;59(12):778-88
pubmed: 24313450
PLoS One. 2017 Apr 6;12(4):e0175224
pubmed: 28384325
Vaccine. 2018 Jan 8;36(3):421-426
pubmed: 29224962
Pathogens. 2020 May 21;9(5):
pubmed: 32455770
Lancet Infect Dis. 2015 Mar;15(3):301-9
pubmed: 25656600
BMC Infect Dis. 2016 Aug 09;16:390
pubmed: 27506837
PLoS Med. 2009 May 26;6(5):e1000081
pubmed: 19468297
Lancet Infect Dis. 2015 May;15(5):535-43
pubmed: 25801458
Clin Infect Dis. 2014 Oct 15;59(8):1066-73
pubmed: 25034421
Clin Infect Dis. 2017 Jan 15;64(2):175-183
pubmed: 27986682
Vaccine. 2017 Apr 25;35(18):2449-2456
pubmed: 28342668
Hum Vaccin Immunother. 2019;15(2):455-458
pubmed: 30261157
PLoS One. 2019 Dec 13;14(12):e0226353
pubmed: 31834926
Can J Public Health. 2012 Jan-Feb;103(1):29-33
pubmed: 22338325
Emerg Infect Dis. 2013 Jul;19(7):1074-83
pubmed: 23763847
Eur Respir J. 2015 Jun;45(6):1632-41
pubmed: 25792633
Front Microbiol. 2016 Oct 14;7:1616
pubmed: 27790208
Pediatr Infect Dis J. 2000 Mar;19(3):187-95
pubmed: 10749457
Am J Epidemiol. 2011 Mar 15;173(6):676-82
pubmed: 21330339
BMC Infect Dis. 2015 Feb 14;15:61
pubmed: 25885764
Semin Respir Crit Care Med. 2009 Apr;30(2):189-209
pubmed: 19296419
J Infect. 2016 Apr;72(4):439-49
pubmed: 26868606
PLoS Med. 2013;10(9):e1001517
pubmed: 24086113
N Engl J Med. 2000 Mar 9;342(10):681-9
pubmed: 10706897
Eur Respir J. 2016 Apr;47(4):1208-18
pubmed: 26797033
Clin Infect Dis. 2016 Jun 15;62(12):1521-6
pubmed: 27105745
J Infect Dis. 1994 Aug;170(2):368-76
pubmed: 8035023
MMWR Morb Mortal Wkly Rep. 2019 Nov 22;68(46):1069-1075
pubmed: 31751323
Lancet Glob Health. 2017 Jan;5(1):e51-e59
pubmed: 27955789
Lancet. 2011 Dec 3;378(9807):1962-73
pubmed: 21492929
Vaccine. 2014 Jun 5;32(27):3452-9
pubmed: 24690148
Vaccine. 2015 Feb 25;33(9):1135-42
pubmed: 25613717
CMAJ Open. 2016 Sep 29;4(3):E545-E550
pubmed: 27730119
N Engl J Med. 2014 Nov 13;371(20):1889-99
pubmed: 25386897